VRCA — Verrica Pharmaceuticals Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1660334 ·
Last close
$3.14
Market Cap
$53.94M
52W High
$9.82
52W Low
$2.77
ADV30
60,234
Next earnings
2026-11-12
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 6,914,000 5,766,000 -12,167,000 -12,407,000 39,861,000 14,394,000 45,835,000
Jun 2026 5,862,000 4,984,000 -11,399,000 -13,153,000 36,017,000 11,198,000 31,710,000
Mar 2026 5,023,000 4,134,000 -9,715,000 -9,682,000 38,786,000 20,600,000 22,731,000
Dec 2025 5,092,000 3,691,000 -6,946,000 -8,074,000 47,131,000 30,147,000 22,388,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-13,347,000
Investing CF
$0
Financing CF
$9,411,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.67
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-347,748,000
Inventory
$2,712,000
Receivables
$11,090,000
ST Investments
—
EBIT TTM
$-27,451,000
Pretax Income TTM
$-31,183,000
Interest Exp TTM
$3,732,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$22,891,000
EBITDA
$-39,729,000
Free Cash Flow
$-9,037,125
Enterprise Value
$73,087,888
Total Cash
$14,394,000
Total Debt
$11,636,000
Shares Out
17,178,786
Trailing EPS
$-2.30
Book Value
$-0.28
ROE
—
ROA
-62.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 35,577,000 -11,939,000 -17,886,000 47,131,000 22,388,000 24,743,000 -17,627,000
Dec 2024 7,566,000 -65,836,000 -76,579,000 54,134,000 63,994,000 -9,860,000 -60,927,000
Dec 2023 5,124,000 -63,222,000 -66,995,000 81,597,000 61,834,000 19,763,000 -38,577,000
Dec 2022 9,032,000 -21,296,000 -24,487,000 44,721,000 4,688,000 40,033,000 -18,650,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$30,321,000
NetIncome TTM
$-31,183,000
OpCashFlow TTM
—
Assets (Latest)
$36,017,000
Forward EPS
$-1.36

Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $4.00 · spot: $2.86 · call volume: 645 · put volume: 13
Expected Move to 2027-03-19: ±$2.19 (76.71%) — implied range $0.67 – $5.05 · ATM straddle on $4.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
INCR Intercure Ltd. $54.16M $3.61 —
HRTX HERON THERAPEUTICS, INC. /DE/ $53.70M $0.28 —
XBIT XBiotech Inc. $54.27M $1.78 —
QUCY Quantum Cyber N.V. $54.38M $0.62 —
IBO IMPACT BIOMEDICAL INC. $53.31M $6.17 —

News headlines (Yahoo Finance, 1h cache)

Verrica (VRCA) Q3 2026 Earnings Call Transcript
2026-11-13 16:30 · Yahoo
Verrica Pharmaceuticals Q3 Earnings Call Highlights
2026-11-13 06:14 · Yahoo
Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
2026-11-12 21:16 · Yahoo
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
2026-11-10 13:00 · Yahoo
Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
2026-11-05 13:00 · Yahoo
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
2026-10-22 12:00 · Yahoo
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
2026-09-30 12:00 · Yahoo
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
2026-09-10 12:05 · Yahoo
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Verrica completes enrolment in Phase III trial of Ycanth
2026-08-28 10:47 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.